These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

372 related items for PubMed ID: 33440319

  • 1. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
    Hu J, Zhang Y, Tang N, Lu Y, Guo P, Huang Z.
    Bioorg Med Chem; 2021 Feb 15; 32():115997. PubMed ID: 33440319
    [Abstract] [Full Text] [Related]

  • 2. Discovery of 4-phenyl-2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as potent and orally active PI3K/mTOR dual inhibitors.
    Yan G, Pu C, Lan S, Zhong X, Zhou M, Hou X, Yang J, Shan H, Zhao L, Li R.
    Eur J Med Chem; 2019 Sep 15; 178():667-686. PubMed ID: 31228810
    [Abstract] [Full Text] [Related]

  • 3. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
    Peng W, Tu ZC, Long ZJ, Liu Q, Lu G.
    Eur J Med Chem; 2016 Jan 27; 108():644-654. PubMed ID: 26731167
    [Abstract] [Full Text] [Related]

  • 4. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
    He R, Xu B, Ping L, Lv X.
    Eur J Med Chem; 2021 Mar 15; 214():113249. PubMed ID: 33561608
    [Abstract] [Full Text] [Related]

  • 5. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
    Han Y, Tian Y, Wang R, Fu S, Jiang J, Dong J, Qin M, Hou Y, Zhao Y.
    Bioorg Chem; 2020 Nov 15; 104():104197. PubMed ID: 32927132
    [Abstract] [Full Text] [Related]

  • 6. XS-2, a novel potent dual PI3K/mTOR inhibitor, exhibits high in vitro and in vivo anti-breast cancer activity and low toxicity with the potential to inhibit the invasion and migration of triple-negative breast cancer.
    Xu S, Sun X, Luo L, Yang Y, Guo Q, Tang S, Jiang Z, Li Y, Han J, Gan W, Yang F, Zhang X, Liu Y, Sun C, He J, Liu M, Zuo D, Zhu W, Wu Y.
    Biomed Pharmacother; 2022 Nov 15; 155():113537. PubMed ID: 36113258
    [Abstract] [Full Text] [Related]

  • 7. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
    Li W, Sun Q, Song L, Gao C, Liu F, Chen Y, Jiang Y.
    Eur J Med Chem; 2017 Dec 01; 141():721-733. PubMed ID: 29107429
    [Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition.
    Li SS, Chen JJ, Zhang MM, Wang WX, Zhang WY, Ma C.
    Eur J Med Chem; 2024 May 05; 271():116425. PubMed ID: 38636129
    [Abstract] [Full Text] [Related]

  • 9. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM, Venkatesan AM, Chen Z, Delos-Santos E, Ayral-Kaloustian S, Brooijmans N, Yu K, Hollander I, Feldberg L, Lucas J, Mallon R.
    Bioorg Med Chem Lett; 2011 Aug 15; 21(16):4773-8. PubMed ID: 21763134
    [Abstract] [Full Text] [Related]

  • 10. Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.
    Zhang B, Zhang Q, Xiao Z, Sun X, Yang Z, Gu Q, Liu Z, Xie T, Jin Q, Zheng P, Xu S, Zhu W.
    Bioorg Chem; 2020 Jan 15; 95():103525. PubMed ID: 31887474
    [Abstract] [Full Text] [Related]

  • 11. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
    Fan YH, Ding HW, Liu DD, Song HR, Xu YN, Wang J.
    Bioorg Med Chem; 2018 May 01; 26(8):1675-1685. PubMed ID: 29475582
    [Abstract] [Full Text] [Related]

  • 12. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D, Teraiya N, Lalwani T, Dalasaniya M, Kapadiya K, Ameta RK, Sangani CB, Duan YT.
    Bioorg Chem; 2024 Jun 01; 147():107323. PubMed ID: 38583254
    [Abstract] [Full Text] [Related]

  • 13. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
    Xu S, Luo L, Sun X, Yang Y, Guo Q, Jiang Z, Wu Y.
    Bioorg Med Chem; 2023 Jan 15; 78():117133. PubMed ID: 36599263
    [Abstract] [Full Text] [Related]

  • 14. BF12, a Novel Benzofuran, Exhibits Antitumor Activity by Inhibiting Microtubules and the PI3K/Akt/mTOR Signaling Pathway in Human Cervical Cancer Cells.
    Gao Y, Ma C, Feng X, Liu Y, Haimiti X.
    Chem Biodivers; 2020 Mar 15; 17(3):e1900622. PubMed ID: 31951313
    [Abstract] [Full Text] [Related]

  • 15. Design, Synthesis, Formulation, and Bioevaluation of Trisubstituted Triazines as Highly Selective mTOR Inhibitors for the Treatment of Human Breast Cancer.
    Sun Q, Chu Y, Zhang N, Chen R, Wang L, Wu J, Dong Y, Li H, Wang L, Tang L, Zhan C, Zhang JQ.
    J Med Chem; 2024 May 09; 67(9):7330-7358. PubMed ID: 38661655
    [Abstract] [Full Text] [Related]

  • 16. Design, synthesis and pharmacological evaluation of 2-arylurea-1,3,5-triazine derivative (XIN-9): A novel potent dual PI3K/mTOR inhibitor for cancer therapy.
    Sun X, Zhang B, Luo L, Yang Y, He B, Zhang Q, Wang L, Xu S, Zheng P, Zhu W.
    Bioorg Chem; 2022 Dec 09; 129():106157. PubMed ID: 36209563
    [Abstract] [Full Text] [Related]

  • 17. Characterization of LY3023414, a Novel PI3K/mTOR Dual Inhibitor Eliciting Transient Target Modulation to Impede Tumor Growth.
    Smith MC, Mader MM, Cook JA, Iversen P, Ajamie R, Perkins E, Bloem L, Yip YY, Barda DA, Waid PP, Zeckner DJ, Young DA, Sanchez-Felix M, Donoho GP, Wacheck V.
    Mol Cancer Ther; 2016 Oct 09; 15(10):2344-2356. PubMed ID: 27439478
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
    Xin P, Li C, Zheng Y, Peng Q, Xiao H, Huang Y, Zhu X.
    Drug Des Devel Ther; 2017 Oct 09; 11():1115-1126. PubMed ID: 28435223
    [Abstract] [Full Text] [Related]

  • 19. PDK1 Inhibitor GSK-470 Exhibits Potent Anticancer Activity in a Pheochromocytoma PC12 Cell Tumor Model via Akt/mTOR Pathway.
    Zhang X, Zhong S.
    Anticancer Agents Med Chem; 2020 Oct 09; 20(7):828-833. PubMed ID: 32188393
    [Abstract] [Full Text] [Related]

  • 20. Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα.
    Yin Y, Sha S, Wu X, Wang SF, Qiao F, Song ZC, Zhu HL.
    Eur J Med Chem; 2019 Nov 15; 182():111630. PubMed ID: 31446244
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.